The study concludes that ANXA1 reduces BBB permeability to protect against sepsis‐induced brain dysfunction via VEGF‐A/VEGF‐R2 regulation of tight junction proteins, suggesting ANXA1 as a potential therapeutic for SAE. This evidence concerns the gene KDR and Sepsis.